COR1

COR1 is a preclinical allogeneic corneal endothelial cell (CEnC) therapy being developed by Lineage Cell Therapeutics for the treatment of corneal endothelial diseases, including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. Manufactured using the proprietary AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent cell Engineering) platform, COR1 consists of off-the-shelf corneal endothelial cells derived from a single pluripotent stem cell line. The therapy's mechanism of action involves the transplantation of these cells into the eye to replace damaged or dysfunctional endogenous endothelial cells, thereby restoring the cornea's ability to regulate fluid balance and maintain transparency. This approach aims to provide a standardized alternative to cadaveric donor tissue, which is currently limited by global shortages and quality inconsistencies.